Skip to main content
Avalo Therapeutics, Inc. (AVTX)
NASDAQ: AVTX · Real-Time Price · USD
4.785
-0.095 (-1.95%)
Apr 25, 2025, 12:46 PM EDT - Market open

Avalo Therapeutics Revenue

In the year 2024, Avalo Therapeutics had annual revenue of $441.00K, down -77.08%. Avalo Therapeutics had revenue of $192.00K in the quarter ending December 31, 2024, a decrease of -66.37%.

Revenue (ttm)
$441.00K
Revenue Growth
-77.08%
P/S Ratio
48.98
Revenue / Employee
$19,174
Employees
23
Market Cap
51.07M

Revenue Chart

History

Fiscal Year End Revenue Change Growth
Dec 31, 2024441.00K-1.48M-77.08%
Dec 31, 20231.92M-16.13M-89.34%
Dec 31, 202218.05M12.65M234.40%
Dec 31, 20215.40M-1.30M-19.42%
Dec 31, 20206.70M-51.35K-0.76%
Dec 31, 2019 Pro Pro Pro
Dec 31, 2018 Pro Pro Pro
Dec 31, 2017 Pro Pro Pro
Dec 31, 2016 Pro Pro Pro
Dec 31, 2015 Pro Pro Pro
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.

Revenue Definition

Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.

Full Definition

Related Stocks

Company Name Revenue
UnitedHealth Group 410.06B
Johnson & Johnson 89.33B
Merck & Co. 64.17B
AbbVie 56.33B
AstraZeneca 54.07B
Novartis AG 51.72B
Eli Lilly and Company 45.04B
Thermo Fisher Scientific 42.88B
Revenue Rankings

AVTX News

More News